title: Management of anemia in patients with congestive heart failure.
abstract: Anemia is an independent risk factor for adverse patient outcomes. There are no guidelines for management of anemia in patients with congestive heart failure (CHF), despite its high incidence. Four objectives were defined by the International Anemia Management and Clinical Outcomes Expert Panel (AMCO), a multinational group of interdisciplinary experts identified by the Society for the Advancement of Blood Management (SABM) to: determine the prevalence of anemia in outpatients; to determine the prevalence of hospital-acquired anemia; to assess the impact of anemia management on clinical outcomes such as quality of life and functional status; and to provide recommendations for primary care physicians and specialists for the diagnosis, evaluation, and management of anemia in patients with CHF. Anemia and iron deficiency were confirmed to be highly prevalent in patients with CHF. Intravenous iron therapy improves anemia, cardiac function and exercise tolerance, leading to improvement in quality of life. Anemia management has been demonstrated to be cost-effective. Clinical care pathways to manage anemia in patients with CHF are recommended as best practices in order to improve patient outcomes. Am. J. Hematol. 92:88-93, 2017. © 2016 Wiley Periodicals, Inc.
authors: Department of Pathology and Medicine, Stanford University, Stanford, California.
authors: Lawrence
authors: L
authors: Tim Goodnough
authors: Department of Cardiology, Heart Failure Program, Bellvitge University Hospital and Biomedical Research Institute, Hospitalet de Liobregat, Barcelona, Spain.
authors: Josep
authors: J
authors: Comin-Colet
authors: Department of Critical Care, Critical Care Division, University Hospital "Virgen delRocío" Avda Manuel Siurot s/n, Seville, Spain.
authors: Santiago
authors: S
authors: Leal-Noval
authors: Institute for Patient Blood Management and Bloodless Medicine and Surgery, Englewood Hospital and Medical Center, Englewood, New Jersey.
authors: Sherri
authors: S
authors: Ozawa
authors: Department of Pharmacy, ASHP Pharmacy Residency Program, Investigation Drug Services, Clinical Coordinator for Pharmacy and Therapeutics/Oncology Services, Englewood, New Jersey.
authors: Jacqueline
authors: J
authors: Takere
authors: Department of Medicine, Penn Hematology/Oncology Abramson Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania.
authors: David
authors: D
authors: Henry
authors: Department of Anesthesiology, Englewood Hospital and Medical Center, Englewood, New Jersey.
authors: Mazyar
authors: M
authors: Javidroozi
authors: Department of Hospital Medicine, Temple University School of Medicine, Representing Society of Hospital Medicine, Philadelphia, Pennsylvania.
authors: Benjamin
authors: B
authors: Hohmuth
authors: Department of Anaesthesiology and Reanimation, Hospital Universitaridel Mar, Barcelona, Spain.|Perioperative Medicine Research Group, Hospital del Mar Medical Research Institute. IMIM Coordination of Anemia Working Group España, Spain.
authors: Elvira
authors: E
authors: Bisbe
authors: Senior medical director, Accumen LLC, San Diego, California.
authors: Irwin
authors: I
authors: Gross
authors: Medicine and Surgery, Icahn School of Medicine, New York, New York.|Department of Anesthesiology, Critical Care, Pain and Hyperbaric medicine, Englewood Hospital and Medical Center, TeamHealth Research Institute, Englewood, New Jersey.
authors: Aryeh
authors: A
authors: Shander
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007275:Injections, Intravenous; D058085:Iron Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D015995:Prevalence; D016896:Treatment Outcome
chemical_list: D058085:Iron Compounds